Bladder cancer patients who have an early but aggressive form of the disease that’s unresponsive to the standard of care now have a new treatment option , an implanted Johnson & Johnson drug/device combination product that enables extended local delivery of its drug payload to the organ.

The J&J product, known in development as TAR-200, will be commercialized under the brand name Inlexzo .

Inlexzo was developed for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), which is cancer confined to the lining of the bladder. This cancer may or may not have papillary tumors, which are finger-like growths that form in the tissue lining the inside of the bladder. Standard treatment this type of bladder cancer is Bacillus Calmette-Guérin (BCG), bacteria that prompt an imm

See Full Page